drugset / Trial / NCT07370506

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

NCT07370506

Phase 1/2 Not yet recruiting 36 enrolled Tanta University
RandomizedParallel-groupOpen-labelPrevention

Summary

This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing therapeutic outcomes, and facilitating the safer administration of anthracycline regimens.

Timeline

Start
2026-02
Primary completion
2027-01
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Telmisartan Other / unclassified Oral
Background Doxorubicin Other / unclassified